Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors

被引:123
作者
El Andaloussi, Abdeljabar [1 ]
Sonabend, Adam M. [1 ]
Han, Yu [1 ]
Lesniak, Maciej S. [1 ]
机构
[1] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA
关键词
toll-like receptor (TLR); CpG; glioma; apoptosis; immunotherapy; regulatory T cell;
D O I
10.1002/glia.20401
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Toll-like receptors (TLRs) recognize a set of conserved molecular structures, so called pathogen-associated molecular patterns, which allow them to sense and initiate innate and adaptive immune responses. In this study, we examined the expression of TLRs in both human and murine glioma. We then analyzed the change in TLR expression after treatment with synthetic phosphorothioate oligodeoxynucleotides (ODNs) containing unmethylated CpG dinucleotides (CpG ODNs), strong activators of both innate and adaptive immunity. In addition, we investigated the in vivo effect of CpG injection into C57BL/6 mice implanted with syngeneic GL261 glioma. Our results indicate that TLR9 is overexpressed in human and murine glioma cell lines and CpG stimulation prolongs the survival of mice with experimental brain tumors. CpGs induce TLR9 down-regulation, followed by apoptosis of GL261 cells in vitro as well as in vivo. Furthermore, the effects of CpG stimulation appear to enhance the antigen presenting capacity of microglia, shift the immune response toward CD8(+) T cells, and decrease the number of CD4(+)CD25(+) regulatory T cells. Taken together, our data support the role of CpG in glioma immunotherapy and provide a rationale for further clinical development of CpG therapy in patients with malignant glioma. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:526 / 535
页数:10
相关论文
共 48 条
  • [1] Toll-like receptors: critical proteins linking innate and acquired immunity
    Akira, S
    Takeda, K
    Kaisho, T
    [J]. NATURE IMMUNOLOGY, 2001, 2 (08) : 675 - 680
  • [2] Auf G, 2001, CLIN CANCER RES, V7, P3540
  • [3] Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Carpentier, A
    Laigle-Donadey, F
    Zohar, S
    Capelle, L
    Behin, A
    Tibi, A
    Martin-Duverneuil, N
    Sanson, M
    Lacomblez, L
    Taillibert, S
    Puybasset, L
    Van Effenterre, R
    Delattre, JY
    Carpentier, AF
    [J]. NEURO-ONCOLOGY, 2006, 8 (01) : 60 - 66
  • [4] Carpentier AF, 2000, CLIN CANCER RES, V6, P2469
  • [5] RETRACTED: DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA (Retracted Article)
    Chu, WM
    Gong, X
    Li, ZW
    Takabayashi, K
    Ouyang, HH
    Chen, Y
    Lois, A
    Chen, DJ
    Li, GC
    Karin, M
    Raz, E
    [J]. CELL, 2000, 103 (06) : 909 - 918
  • [6] Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538
  • [7] Immunostimulatory CpG-DNA activates murine microglia
    Dalpke, AH
    Schäfer, MKH
    Frey, M
    Zimmermann, S
    Tebbe, J
    Weihe, E
    Heeg, K
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (10) : 4854 - 4863
  • [8] Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
    Diebold, SS
    Kaisho, T
    Hemmi, H
    Akira, S
    Sousa, CRE
    [J]. SCIENCE, 2004, 303 (5663) : 1529 - 1531
  • [9] Influence of C6 and CNS1 brain tumors on methotrexate pharmacokinetics in plasma and brain tissue
    Dukic, SF
    Kaltenbach, ML
    Heurtaux, T
    Hoizey, G
    Lallemand, A
    Vistelle, R
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) : 131 - 138
  • [10] Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells
    Häcker, H
    Mischak, H
    Häcker, G
    Eser, S
    Prenzel, N
    Ullrich, A
    Wagner, H
    [J]. EMBO JOURNAL, 1999, 18 (24) : 6973 - 6982